ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Autoimmune Hepatitis

In brief

VAY736 dose testing; VAY736 efficacy and safety testing.

Key facts

Study ID
NCT03217422
Run by
Novartis Pharmaceuticals
People needed
68
Starts
2018-02-15
Expected to finish
2025-12-17
Last updated by the study team
2026-02-19

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.